Takahashi H, Kawazoe K, Fujita S, Okabe H, Hideshima K, Tsuda N, Tezuka F
Department of Oral Pathology, Nagasaki University School of Dentistry, Japan.
Pathol Res Pract. 1996 Jan;192(1):44-53. doi: 10.1016/S0344-0338(96)80129-4.
The B-cell leukemia/lymphoma-2 (bcl-2) proto-oncogene is peculiar, as its product appears to provide survival advantage to B cells by blocking apoptosis. Expression of bcl-2 protein was analyzed in 54 cases of primary non-Hodgkin's malignant lymphomas of the oral cavity by immunohistologic staining of paraffin-embedded tissue. The immunophenotype of each tumor was established with the use of a panel of monoclonal and polyclonal antibodies to lymphoid cell differentiation antigens. The cases in the present study were 42 B-cell lymphomas, 7 T-cell lymphomas and 5-lymphomas revealing histiocytic markers. Sixteen of the 42 B-cell lymphomas were positive for bcl-2 protein, and were composed of 7 low-grade B-cell lymphomas and 9 high-grade B-cell lymphomas. Seven low-grade B-cell lymphomas were composed of one mucosa-associated lymphoid tissue type, three centrocytic types and three centroblastic-centrocytic types. Nine high-grade B-cell lymphomas comprised four centroblastic types, one immunoblastic type and four lymphoblastic types. Enhanced expression of the bcl-2 oncogenic protein was detectable in lymphoma cells in 2 cases for the T-cell lymphoma, and one case for the true histiocytic lymphoma. In contrast to the previous reports of American node-based lymphomas, Japanese primary oral lymphomas in our series expressed a lower frequency of bcl-2 protein. Furthermore, the present study indicated that bcl-2 protein was expressed on a wide variety of B-cell lymphomas, T-cell lymphomas and true histiocytic lymphoma, and that differences in bcl-2 protein expression may be useful in the diagnostic separation of lymphoblastic lymphoma with B-cell marker from Burkitt's lymphoma.
B细胞白血病/淋巴瘤-2（bcl-2）原癌基因很独特，因为其产物似乎通过阻断细胞凋亡为B细胞提供生存优势。通过对石蜡包埋组织进行免疫组织化学染色，分析了54例口腔原发性非霍奇金恶性淋巴瘤中bcl-2蛋白的表达情况。使用一组针对淋巴细胞分化抗原的单克隆和多克隆抗体确定每个肿瘤的免疫表型。本研究中的病例包括42例B细胞淋巴瘤、7例T细胞淋巴瘤和5例显示组织细胞标志物的淋巴瘤。42例B细胞淋巴瘤中有16例bcl-2蛋白呈阳性，包括7例低度B细胞淋巴瘤和9例高度B细胞淋巴瘤。7例低度B细胞淋巴瘤包括1例黏膜相关淋巴组织型、3例中心细胞型和3例中心母细胞-中心细胞型。9例高度B细胞淋巴瘤包括4例中心母细胞型、1例免疫母细胞型和4例淋巴母细胞型。在2例T细胞淋巴瘤和1例真性组织细胞淋巴瘤的淋巴瘤细胞中可检测到bcl-2致癌蛋白的表达增强。与先前关于美国淋巴结型淋巴瘤的报道相反，我们系列中的日本原发性口腔淋巴瘤bcl-2蛋白表达频率较低。此外，本研究表明bcl-2蛋白在多种B细胞淋巴瘤、T细胞淋巴瘤和真性组织细胞淋巴瘤中表达，并且bcl-2蛋白表达的差异可能有助于诊断性区分具有B细胞标志物的淋巴母细胞淋巴瘤和伯基特淋巴瘤。
